Literature DB >> 27106721

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.

Geraldine F Clough1, Keith G McCormick1, Eleonora Scorletti1,2, Lokpal Bhatia1,2, Philip C Calder1,2, Michael J Griffin3, Christopher D Byrne4,5.   

Abstract

AIMS/HYPOTHESIS: The effect of n-3 fatty acid treatment on temperature perception as a sensory nerve function modality is uncertain. In patients with non-alcoholic fatty liver disease (NAFLD) both with and without type 2 diabetes, we: (1) tested whether 15-18 months' treatment with 4 g/day of docosahexaenoic plus eicosapentaenoic acid (DHA+EPA) improved hot (HPT) and cold (CPT) temperature perception thresholds and (2) explored factors associated with HPT and CPT, in a randomised, double-blind, placebo-controlled trial.
METHODS: The effect of treatment (n = 44) on HPT, CPT and temperature perception index (TPI: difference between HPT and CPT) was measured at the big toe in 90 individuals without neuropathy (type 2 diabetes; n = 30). Participants were randomised 1:1, using sequential numbering, by personnel independent from the trial team. All participants and all members of the research team were blinded to group assignment. Data were collected in the Southampton National Institute for Health Research Biomedical Research Centre. Treatment effects and the independence of associations were testing by regression modelling.
RESULTS: Mean ± SD age was 50.9 ± 10.6 years. In men (n = 53) and women (n = 37), HPTs (°C) were 46.1 ± 5.1 and 43.1 ± 6.4 (p = 0.02), CPTs (°C) were 22.7 ± 3.4 and 24.5 ± 3.6 (p = 0.07) and TPIs (°C) were 23.4 ± 7.4 and 18.7 ± 9.5 (p = 0.008), respectively. In univariate analyses, total body fat percentage (measured by dual-energy x-ray absorptiometry [DXA]) was associated with HPT (r = -0.36 p = 0.001), CPT (r = 0.35 p = 0.001) and TPI (r = 0.39 p = 0.0001). In multivariable-adjusted regression models, adjusting for age, sex and other potential confounders, only body fat percentage was independently associated with HPT, CPT or TPI (p = 0.006, p = 0.006 and p = 0.002, respectively). DHA+EPA treatment did not modify HPT, CPT or TPI (p = 0.93, p = 0.44 and p = 0.67, respectively). There were no important adverse effects or side effects reported. CONCLUSIONS/
INTERPRETATION: Higher body fat percentage is associated with enhanced temperature perception. There was no benefit of treatment with high-dose n-3 fatty acids on the thresholds to detect hot or cold stimuli. TRIAL REGISTRATION: ClinicalTrials.gov NCT00760513 FUNDING: This work was supported by the National Institute for Health Research through the NIHR Southampton Biomedical Research Unit grant and by a Diabetes UK allied health research training fellowship awarded to KMcC (Diabetes UK. BDA 09/0003937).

Entities:  

Keywords:  Insulin resistance; Microcirculation; Non-alcoholic fatty liver disease; Omacor/Lovaza; Small sensory nerves; Temperature perception threshold; Type 2 diabetes; n-3 Fatty acid

Mesh:

Substances:

Year:  2016        PMID: 27106721     DOI: 10.1007/s00125-016-3966-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  36 in total

1.  Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology.

Authors:  R A Malik; A Veves; D Walker; I Siddique; R H Lye; W Schady; A J Boulton
Journal:  Acta Neuropathol       Date:  2001-04       Impact factor: 17.088

2.  Reproducibility and influence of test modality order on thermal perception and thermal pain thresholds in quantitative sensory testing.

Authors:  Victoria Heldestad; Jan Linder; Lisa Sellersjö; Erik Nordh
Journal:  Clin Neurophysiol       Date:  2010-05-15       Impact factor: 3.708

3.  Quantitative thermal sensory testing -- value of testing for both cold and warm sensation detection in evaluation of small fiber neuropathy.

Authors:  Garima Shukla; Manvir Bhatia; Madhuri Behari
Journal:  Clin Neurol Neurosurg       Date:  2005-10       Impact factor: 1.876

4.  Treatment of diabetic sensory polyneuropathy.

Authors:  Lindsay Zilliox; James W Russell
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

5.  The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden.

Authors:  Lars Kärvestedt; Eva Mårtensson; Valdemar Grill; Stig Elofsson; Gunvor von Wendt; Anders Hamsten; Kerstin Brismar
Journal:  J Diabetes Complications       Date:  2010-05-21       Impact factor: 2.852

Review 6.  Small-Fiber Neuropathy: A Diabetic Microvascular Complication of Special Clinical, Diagnostic, and Prognostic Importance.

Authors:  A E Körei; I Istenes; N Papanas; P Kempler
Journal:  Angiology       Date:  2015-05-08       Impact factor: 3.619

7.  Current glycaemic control has no impact on the advancement of diabetic neuropathy.

Authors:  Piotr Dziemidok; Grzegorz Szcześniak; Ewa Kostrzewa-Zabłocka; Piotr Paprzycki; Anna Korzon-Burakowska
Journal:  Ann Agric Environ Med       Date:  2012       Impact factor: 1.447

8.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Authors:  Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

9.  A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy.

Authors:  Niral Patel; Vishal Mishra; Prakruti Patel; Ram K Dikshit
Journal:  J Diabetes Metab Disord       Date:  2014-05-27

10.  Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden.

Authors:  Lars Kärvestedt; Eva Mårtensson; Valdemar Grill; Stig Elofsson; Gunvor von Wendt; Anders Hamsten; Kerstin Brismar
Journal:  Diabetes Care       Date:  2008-11-25       Impact factor: 17.152

View more
  5 in total

1.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-30

2.  Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Nicole Martin; Charlene Bridges; Julii S Brainard; Xia Wang; Tracey J Brown; Sarah Hanson; Oluseyi F Jimoh; Sarah M Ajabnoor; Katherine Ho Deane; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27

Review 3.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18

Review 4.  Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Nicole Martin; Charlene Bridges; Julii S Brainard; Xia Wang; Tracey J Brown; Sarah Hanson; Oluseyi F Jimoh; Sarah M Ajabnoor; Katherine Ho Deane; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18

5.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2020-02-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.